Literature DB >> 29154974

Prostate cancer health disparities: An immuno-biological perspective.

Sanjay Kumar1, Rajesh Singh2, Shalie Malik3, Upender Manne4, Manoj Mishra5.   

Abstract

Prostate cancer (PCa) is the most commonly diagnosed malignancy in males, and, in the United States, is the second leading cause of cancer-related death for men older than 40 years. There is a higher incidence of PCa for African Americans (AAs) than for European-Americans (EAs). Investigations related to the incidence of PCa-related health disparities for AAs suggest that there are differences in the genetic makeup of these populations. Other differences are environmentally induced (e.g., diet and lifestyle), and the exposures are different. Men who immigrate from Eastern to Western countries have a higher risk of PCa than men in their native countries. However, the number of immigrants developing PCa is still lower than that of men in Western countries, suggesting that genetic factors are involved in the development of PCa. Altered genetic polymorphisms are associated with PCa progression. Androgens and the androgen receptor (AR) are involved in the development and progression of PCa. For populations with diverse racial/ethnic backgrounds, differences in lifestyle, diet, and biology, including genetic mutations/polymorphisms and levels of androgens and AR, are risk factors for PCa. Here, we provide an immuno-biological perspective on PCa in relation to racial/ethnic disparities and identify factors associated with the disproportionate incidence of PCa and its clinical outcomes. Published by Elsevier B.V.

Entities:  

Keywords:  Health disparity; Immunotherapy; Prostate cancer

Mesh:

Substances:

Year:  2017        PMID: 29154974      PMCID: PMC5743619          DOI: 10.1016/j.canlet.2017.11.011

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  194 in total

1.  Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls.

Authors:  Samira Syed
Journal:  Cancer       Date:  2003-11-15       Impact factor: 6.860

2.  Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer.

Authors:  Brandon A Mahal; David R Ziehr; Ayal A Aizer; Andrew S Hyatt; Carlos Lago-Hernandez; Toni K Choueiri; Aymen A Elfiky; Jim C Hu; Christopher J Sweeney; Clair J Beard; Anthony V D'Amico; Neil E Martin; Simon P Kim; Christopher S Lathan; Quoc-Dien Trinh; Paul L Nguyen
Journal:  J Geriatr Oncol       Date:  2014-05-23       Impact factor: 3.599

3.  HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses.

Authors:  Vitaly Kochin; Takayuki Kanaseki; Serina Tokita; Sho Miyamoto; Yosuke Shionoya; Yasuhiro Kikuchi; Daichi Morooka; Yoshihiko Hirohashi; Tomohide Tsukahara; Kazue Watanabe; Shingo Toji; Yasuo Kokai; Noriyuki Sato; Toshihiko Torigoe
Journal:  Oncoimmunology       Date:  2017-02-16       Impact factor: 8.110

4.  Interleukin-6 is an autocrine growth factor in human prostate cancer.

Authors:  D Giri; M Ozen; M Ittmann
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

5.  TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells.

Authors:  Xiao-Hui Chen; Zong-Cai Liu; Ge Zhang; Wei Wei; Xiao-Xiong Wang; Hao Wang; Hong-Peng Ke; Fan Zhang; Hong-Sheng Wang; Shao-Hui Cai; Jun Du
Journal:  Mol Immunol       Date:  2015-01-22       Impact factor: 4.407

Review 6.  T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.

Authors:  M A Cheever; W Chen; M L Disis; M Takahashi; D J Peace
Journal:  Ann N Y Acad Sci       Date:  1993-08-12       Impact factor: 5.691

7.  Autologous Hsp70 induces antigen specific Th1 immune responses in a murine T-cell lymphoma.

Authors:  Sanjay Kumar; Praveen Deepak; Sanjay Kumar; Dhiraj Kishore; Arbind Acharya
Journal:  Immunol Invest       Date:  2009       Impact factor: 3.657

8.  Disparities in treatment and outcome for renal cell cancer among older black and white patients.

Authors:  Sonja I Berndt; H Ballentine Carter; Mark P Schoenberg; Craig J Newschaffer
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

9.  Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme.

Authors:  D J Waxman; C Attisano; F P Guengerich; D P Lapenson
Journal:  Arch Biochem Biophys       Date:  1988-06       Impact factor: 4.013

10.  Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway.

Authors:  Andressa Ardiani; Sofia R Gameiro; Anna R Kwilas; Renee N Donahue; James W Hodge
Journal:  Oncotarget       Date:  2014-10-15
View more
  8 in total

1.  Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences.

Authors:  Walter Rayford; Alp Tuna Beksac; Jordan Alger; Mohammed Alshalalfa; Mohsen Ahmed; Irtaza Khan; Ugo G Falagario; Yang Liu; Elai Davicioni; Daniel E Spratt; Edward M Schaeffer; Felix Y Feng; Brandon Mahal; Paul L Nguyen; Robert B Den; Mark D Greenberger; Randy Bradley; Justin M Watson; Matthew Beamer; Lambros Stamatakis; Darrell J Carmen; Shivanshu Awasthi; Jonathan Hwang; Rachel Weil; Harri Merisaari; Nihal Mohamed; Leslie A Deane; Dimple Chakravarty; Kamlesh K Yadav; Kosj Yamoah; Sujit S Nair; Ashutosh K Tewari
Journal:  Commun Biol       Date:  2021-06-03

Review 2.  Multiple pathogens and prostate cancer.

Authors:  James S Lawson; Wendy K Glenn
Journal:  Infect Agent Cancer       Date:  2022-05-30       Impact factor: 3.698

3.  Identification of microenvironment related potential biomarkers of biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma.

Authors:  Xiaoru Sun; Lu Wang; Hongkai Li; Chuandi Jin; Yuanyuan Yu; Lei Hou; Xinhui Liu; Yifan Yu; Ran Yan; Fuzhong Xue
Journal:  Aging (Albany NY)       Date:  2021-06-16       Impact factor: 5.682

4.  Database Mining of Genes of Prognostic Value for the Prostate Adenocarcinoma Microenvironment Using the Cancer Gene Atlas.

Authors:  Xin Zhao; Daixing Hu; Jia Li; Guozhi Zhao; Wei Tang; Honglin Cheng
Journal:  Biomed Res Int       Date:  2020-05-18       Impact factor: 3.411

5.  Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts.

Authors:  Dominick Bossé; Wanling Xie; Xun Lin; Ronit Simantov; Aly-Khan A Lalani; Jeffrey Graham; J Connor Wells; Frede Donskov; Brian Rini; Benoit Beuselinck; Ajjai Alva; Aaron Hansen; Lori Wood; Denis Soulières; Christian Kollmannsberger; Francois Patenaude; Daniel Y C Heng; Toni K Choueiri; Rana R McKay
Journal:  JCO Glob Oncol       Date:  2020-02

Review 6.  A narrative review of sociodemographic risk and disparities in screening, diagnosis, treatment, and outcomes of the most common extrathoracic malignancies in the United States.

Authors:  Sarah Singh; Praveen Sridhar
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

Review 7.  Advances of Zinc Signaling Studies in Prostate Cancer.

Authors:  Dangdang Li; Daniel B Stovall; Wenmeng Wang; Guangchao Sui
Journal:  Int J Mol Sci       Date:  2020-01-19       Impact factor: 5.923

Review 8.  Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies.

Authors:  Zachary S Dovey; Sujit S Nair; Dimple Chakravarty; Ashutosh K Tewari
Journal:  Cancer Rep (Hoboken)       Date:  2021-02-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.